| DB ID | MyCo_2077 |
| Title | Serum interleukin-18 and soluble tumour necrosis factor receptor 2 are associated with disease severity in patients with paracoccidioidomycosis |
| Year | 2007 |
| PMID | 17302897 |
| Fungal Diseases involved | Paracoccidioidomycosis |
| Associated Medical Condition | None |
| Genus | Paracoccidioides |
| Species | brasiliensis |
| Organism | Paracoccidioides brasiliensis |
| Ethical Statement | The study protocol was approved by the Ethics Committee of State University of Campinas Medical School (SP, Brazil). |
| Site of Infection | None |
| Opportunistic invasive | None |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | CXCL10 |
| Biomarker Full Name | CXCL10 |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Brazil |
| Cohort | Patients with PCM cared for at the University Clinical Hos- pital of UNICAMP, Campinas – SP, Brazil, were grouped according to the clinical form in JF and AF. Here analysed 23 sera from patients with JF (14 males and nine females, age 6–41 years) and 18 sera from patients with AF (15 males and three females, age 33–69 years) of PCM. We also analysed 21 healthy controls (C, 16 males and five females, age 21–62 years). |
| Cohort No. | 45 Patients and 21 control |
| Age Group | Jun-73 |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Paracoccidioidomycosis (PCM) is a deep mycosis endemic in various countries of Latin America, mainly in Brazil. The aetiological agent of PCM is the thermodimorphic fungus Paracoccidioides brasiliensis The disease presents a broad spectrum of clinical and pathological manifestations, ranging from benign and localized forms to severely disseminated disease. According to the current classification the adult or chronic progressive form of the disease (AF) affects predominantly adult males, with a high frequency of pulmonary, skin, adrenal and visceral involvement. In clear contrast to the adult type, the juvenile type (JF) affects equally young patients of both sexes and is characterized by systemic lymph node involvement, hepatosplenomegaly and bone marrow dysfunction, resem- bling a lymphoproliferative disease. Patients with AF usually exhibit low levels of specific antibodies and adequate cellular immune responses, while those with the JF typically show high levels of specific antibodies, polyclonal activation of B cells, antigenaemia and impaired cellular immune responses. |
| Technique | ELISA |
| Analysis Method | ELISA Based |
| ELISA kits | ELISA Kit(R&D Systems, Minneapolis, MN, USA), (MBL: Medical & Biological Laboratories, Nagoya, Japan) |
| Assay Data | None |
| Validation Techniques used | ELISA |
| Up Regulation Down Regulation | Increase |
| Sequence Data | None |
| External Link | None |
